 Movings toward the utilization of all donated liver grafts. The “b-list” concept

Vrochides D\textsuperscript{1,2}, Metrakos P\textsuperscript{1}

\textsuperscript{1}Multi-Organ Transplant Program, Royal Victoria Hospital, McGill University, Montreal, QC, Canada
\textsuperscript{2}Center for Hepato-Pancreato-Biliary Surgery, Euromedica Geniki Kliniki, Thessaloniki, Greece

Abstract

The number of available liver grafts is not sufficient to meet the current demand. A significant number of patients succumb before they receive a liver graft. However, approximately 10% of marginal livers are considered unsuitable for donation and are discarded. Calculating the primary non-function probability for any given liver graft can be performed using prognostic tools, such as the Donor Risk Index and the Eurotransplant Donor Risk Index. On the other hand, mortality on the waiting list, which is sometimes more than 15% per year of enlistment, directly correlates with its size, the graft supply and the gravity of the potential recipients’ clinical condition. Up to 30% of the potential recipients will never receive a graft.

The purpose of this invited commentary is to examine whether the literature supports the utilization of the marginal liver grafts that would otherwise be discarded. It appears that there is sufficient evidence in favor of the development of a “B-list” for potential liver graft recipients. It should comprise all of the candidates who were definitely removed from the primary waiting list or were never included. The potential “B-list” recipients should only be eligible to receive grafts that would otherwise be discarded, i.e., “B-livers”. Enrollment in a “B-list” might not only increase the overall patient survival (enlisted and transplanted combined) but might also improve candidate quality of life by maintaining their hope for a cure.

Keywords: Liver transplantation, organ allocation, marginal grafts, waiting list, equity, utility

Corresponding author: Dionisios Vrochides, Center of Hepato-Pancreato-Biliary Surgery, Euromedica Geniki Kliniki, 2 Gravias Str., Thessaloniki, 54645, Greece. Tel: +302310895469. Fax: +302310220732, e-mail: info@vrochides.com

Background

It is well known that the number of available liver grafts is not sufficient to meet the current demand. For this reason, grafts are allocated according to the gravity of the clinical condition of the potential recipients, i.e., patients are transplanted according the principle of equity. Using the MELD score to prioritize the liver transplantation waiting listing follows this principle of equity\textsuperscript{1}. However, due to the organ shortage, a significant number of patients succumb before they receive a liver graft\textsuperscript{2}. Nonetheless, many marginal livers are considered unsuitable for donation and are not utilized, particularly during the last decade, because the percentage of older donors has increased significantly\textsuperscript{3}. One wonders whether discarded grafts could be used under certain circumstances. Is there sufficient bibliographic evidence to support the utilization of the marginal liver grafts that would be otherwise discarded in patients who were withdrawn from the recipient list or were never included because they did not meet certain criteria? To answer this question, the definition of a marginal unusable liver graft needs to be clarified. In addition, specific criteria for adding and removing patients from the recipient list should be agreed upon. All patients not included on the primary list could then be added to a secondary waiting list, the “B-list”, to receive an otherwise unusable but potentially life-saving liver graft.

Keywords:

Liver transplantation, organ allocation, marginal grafts, waiting list, equity, utility

Corresponding author: Dionisios Vrochides, Center of Hepato-Pancreato-Biliary Surgery, Euromedica Geniki Kliniki, 2 Gravias Str., Thessaloniki, 54645, Greece. Tel: +302310895469. Fax: +302310220732, e-mail: info@vrochides.com

Defining the marginal unusable graft

The definition of the extended criteria donor (ECD) is certainly different from that of the extended criteria graft (ECG). An ECD yields a liver graft that has an increased probability of primary non-function (PNF) when compared to a graft procured by an “ideal” donor, i.e., donors less than 40 years old who are hemodynamically stable with non-steatotic livers\textsuperscript{4}. The incidence of PNF when a liver from an «ideal» donor is transplanted to the average recipient is 8.1%. For this reason, donors are characterized as ECDs under the following conditions: older than 65 years; hemodynamically stable; macrovesicular steatosis greater than 30%; serum sodium greater than 155 mEq/l; γGT greater than 200 IU/l; and more than 5 days in the ICU\textsuperscript{5-8}. In addition, every donor that carries a transmittable disease is considered an ECD. Currently, under specific circumstances, patients with tumors of the central nervous system or the urogenital system, microbial infections (even meningitis) or HBV, HCV or HIV are acceptable donors\textsuperscript{5,9}.

Every ECD graft is characterized as an ECG. In addition, grafts that are procured from non-ECDs may iatrogenically become ECGs. For example, livers with a cold ischemia time greater than 12 hours are considered...
Moreover, ECGs include all grafts with a warm ischemia time greater than 60 minutes. In addition, all segmental grafts (LDLTx, SLTx) are characterized as ECGs because the incidence of PNF is 13%12. Finally, livers procured from non-heart-beating donors are considered ECGs because the incidence of PNF is more than 15%13.

The characterization of donated livers as ECGs is secondary to the increased probability of PNF in 75% of the cases, whereas in the remaining 25%, the characterization is due to the presence of a transmittable disease. Because grafts with a transmittable viral disease can be transplanted into patients that already carry the disease and because bacterial infections or the aforementioned neoplasias are almost never (≤ 1%) transmitted to recipients, the debate about the allocation of ECGs concerns only livers with an increased probability of PNF. Therefore, the prediction of the probability of PNF for an ECG is of paramount importance.

Calculating the PNF probability for any given liver graft can be performed using prognostic tools, such as the Donor Risk Index (DRI)14. The DRI is a log number that is calculated by a multivariate equation and lies between 0.0 (“best” graft) and 2.8 (“worst” graft). The “ideal” donor DRI is 1.0. The variables in the equation include donor age and height and cold ischemia time. Using the DRI, the predicted survival of the “average” recipient in the USA can be calculated in relation to the quality of the received graft (Table 1). For example, the one-year survival rates of the “average” recipient in USA are 88%, 80% and 71% for transplanted liver DRIs of 1.0, 1.6 and 2.0, respectively14. Similar calculations can be made with another prognostic tool, the Eurotransplant DRI. This index utilizes all the parameters of DRI with the exception of height and race and the addition of latest serum GGT and rescue allocation. It is a prognostic tool which predicts the quality of a specific liver graft that is transplanted within the Eurotransplant region15.

Approximately 20% of the donated livers are considered ECGs, and one out of three (7% of the total) is discarded, primarily due to the fear of PNF. Indeed, the higher the DRI, the greater the chance that a donated liver will not be transplanted. For example, only 3.1% of grafts with a DRI = 1.0 are not transplanted, whereas one out of eight (12.5%) grafts with a DRI = 2.0 are not used.

### Reasons for withdrawal or non-enrollment on the liver transplant waiting list

The three most common reasons (other than receiving a transplant) for any potential liver recipient’s withdrawal from the waiting list are: i) death while waiting; ii) significant deterioration of the clinical condition, which is typically reflected by a rise in the MELD score; and iii) for patients with hepatocellular cancer, an increase of the neoplastic load beyond the established criteria that the center follows (e.g., Milan, UCSF). In the last two cases, patients are withdrawn from the list (or primary non-enrollment) to maintain an average five-year liver recipient survival of at least 50%

### Table 1: Prediction of the mean recipient survival (3 months, 12 months and 36 months) based on graft quality, as measured by the DRI14.

<table>
<thead>
<tr>
<th>DRI (≤ 1.0)</th>
<th>Survival (%) 3 m</th>
<th>Survival (%) 12 m</th>
<th>Survival (%) 36 m</th>
</tr>
</thead>
<tbody>
<tr>
<td>≤ 1.0</td>
<td>92</td>
<td>88</td>
<td>81</td>
</tr>
<tr>
<td>= 1.2</td>
<td>90</td>
<td>84</td>
<td>75</td>
</tr>
<tr>
<td>= 1.4</td>
<td>89</td>
<td>82</td>
<td>74</td>
</tr>
<tr>
<td>= 1.6</td>
<td>86</td>
<td>80</td>
<td>70</td>
</tr>
<tr>
<td>= 1.8</td>
<td>84</td>
<td>77</td>
<td>69</td>
</tr>
<tr>
<td>&gt; 2.0</td>
<td>80</td>
<td>71</td>
<td>60</td>
</tr>
</tbody>
</table>

DRI: Donor Risk Index.
VROCHIDES D

Regarding the respiratory system, withdrawal from the list because their perioperative mortality rate, it needs to be stressed that these patients enjoy the highest survival benefit (up to 300 times) from liver transplantation (Table 2).

The number of candidates with hepatocellular cancer that are removed from the waiting list (or not enrolled) due to increased tumor load, is dependent on the following: i) the transplantation criteria adopted by each specific center (e.g., Milan, UCSF), ii) the number of patients with hepatocellular cancer, iii) the size of the waiting list, iv) the gravity of the candidate’s cirrhosis and v) the graft supply. Each year, approximately 25% of the potential recipients with hepatocellular cancer are removed from the waiting list due to increases in their neoplastic loads.

Developing the “B-list” for liver transplant candidates

Based on the aforementioned facts and observations, it is clear that slightly less than 10% of donated livers are discarded. However, up to 30% of potential recipients will never receive a graft either because they succumb while waiting or because they are removed from the list. Of course, candidate removal from the waiting list invariably leads to their demise either due to the deterioration of liver function or secondary to the dissemination of hepatocellular cancer. Moreover, death is the only outcome for all of the patients not initially enrolled on the waiting list.

The “B-list” concept is simple. All potential candidates who were removed from the primary waiting list (the “A-list”) or were not initially enrolled due to any medical reason should be placed on a secondary waiting list, the “B-list”. The potential “B-list” recipients should be eligible to receive only livers that would otherwise be discarded, i.e., they would not be implanted into a patient on the primary waiting list (“B-livers”). Obtaining consent for a “B-liver” transplantation (a “B-liver” to a “B-list” recipient) should be a very detailed and lengthy process approved by the ethical committee of each transplantation center and should adhere to strict algorithms. In this manner, no patient will stay off the list and almost no grafts will be discarded.

The development of the “B-list” will no doubt increase the average immediate postoperative mortality because patients and grafts of “poor quality” will lead to more complications. However, it will increase the cumulative survival of both the transplanted and the enlisted patients (intention to treat patients), i.e., it will increase the societal benefit. Indeed, the utilization of liver grafts of the lowest quality (DRI > 1.65) leads to an increased recipient survival, provided that they are transplanted to

Table 2: Survival benefit (in days) for patients after liver transplantation when compared with candidates who are still waiting for a graft. Patients are stratified according to MELD score the day of operation (transplanted patients) or the day of enrollment (non-transplanted patients).

<table>
<thead>
<tr>
<th>MELD</th>
<th>Survival (days) On the list</th>
<th>Survival (days) Post OLTx</th>
</tr>
</thead>
<tbody>
<tr>
<td>18 – 20</td>
<td>1346</td>
<td>2098</td>
</tr>
<tr>
<td>21 – 23</td>
<td>710</td>
<td>2046</td>
</tr>
<tr>
<td>24 – 26</td>
<td>435</td>
<td>2063</td>
</tr>
<tr>
<td>27 – 29</td>
<td>219</td>
<td>1863</td>
</tr>
<tr>
<td>30 – 39</td>
<td>79</td>
<td>1487</td>
</tr>
<tr>
<td>≥ 40</td>
<td>28</td>
<td>1379</td>
</tr>
</tbody>
</table>

OLTx: Orthotopic Liver Transplantation.

recipient’s clinical condition. Approximately 15% of enlisted patients die every year while waiting for a liver transplant.

A potential liver transplant recipient might be deemed too “sick” to transplant for one or more reasons. As far as the cardiovascular system is concerned, all transplant candidates with a coronary artery calcification index > 100 by coronary computed tomography should undergo a dobutamine stress echocardiogram. If the product of the equation $3.78 + 0.07 \times \text{MELD} - 0.05 \times \text{MAHR}$ (maximum achieved heart rate) exceeds zero, the candidate should be removed from the waiting list (or should not be enrolled, if it is the first evaluation). The incidence of serious intraoperative cardiovascular events for such a potential recipient is 47%.

Moreover, candidates with a mean pulmonary arterial pressure > 35 mmHg (under treatment) should be withdrawn from the list because their perioperative mortality exceeds 50%. Regarding the respiratory system, when the potential recipient’s $\text{P}_{\text{O}_2}/\text{Fi}_2$ ratio is less than 100, 70% of the treating transplant physicians suggest removal from the list. Finally, withdrawal from or non-enrollment on the liver transplant waiting list is justified when the candidate is of advanced age (> 70 years old), develops a serious infection, is greatly malnourished (> 20% of his body weight), continues to abuse substances or suffers from irreversible central nervous system damage.

When a candidate’s clinical condition deteriorates, his MELD score usually worsens. However, an increase in the MELD score alone, i.e., deterioration of the hepatic and/or renal function alone, without deterioration of any other system (e.g., cardiovascular, respiratory), should never lead to their removal from the list. A successful liver transplantation restores normal liver and, in most cases, renal function. Moreover, if renal function is unlikely to be restored after receiving a hepatic graft (i.e., estimated GFR constantly < 30 ml/min/1.73m² for > 90 days), a combined liver/kidney transplant can be considered. Although patients with higher MELD scores have a higher perioperative mortality rate, it needs to be noted that these patients enjoy the highest survival benefit (up to 300 times) from liver transplantation (Table 2).

OLTx: Orthotopic Liver Transplant.
patients with a MELD score higher than 20 (Figure 1)\textsuperscript{24}. In addition, the five-year survival rate after liver transplantation for hepatocellular cancer beyond any established criteria is 11%\textsuperscript{25}.

Conclusion

The development of a “B-list” for liver transplant candidates will increase the overall patient survival (enlisted and transplanted combined) because patients without any chance of survival (those not included on the primary list) will have some probability of staying alive by receiving a “low-quality” liver graft, which, until recently, was fully functional in the donor. In addition, if the initially discarded liver grafts are allocated according to some simple principles (e.g., recipients should have a MELD score higher than 20, HCV patients will be transplanted with organs from young donors\textsuperscript{26}), survival will be even greater. Finally, enrollment of these gravely ill patients on some type of list (in this case a “B-list”) maintains their hope for cure and improves their quality of life regardless of the liver transplant outcome.

Disclosures

This is an original article submitted as an invited commentary.

This manuscript is not based on a previous communication.

There were no sources of funding for this publication.

There are no conflicts of interest for any of the authors.

References


